Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition

In research published this week, scientists have found that a therapy originally developed to treat Alzheimer’s Disease could hold promise for children with T-cell acute lymphoblastic leukaemia. An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and Children’s Cancer Institute, Australia, have identified a novel therapy for T-cell acute lymphoblastic leukaemia

Read More


Are industry-funded charities promoting “advocacy-led studies” or “evidence-based science”?: a case study of the International Life Sciences Institute

Source The Guardian International Life Sciences Institute used by corporate backers to counter public health policies, says study An institute whose experts have occupied key positions on EU and UN regulatory panels is, in reality, an industry lobby group that masquerades as a scientific health charity, according to a peer-reviewed study. The Washington-based International Life Sciences

Read More


Regulatory intelligence: Update on regenerative medicine advanced therapies designations

This article discusses the scope and purpose of the special designation for Regenerative Medicine Advanced Therapies (RMAT) created by the passage of the 21st Century Cures Act. The authors explain the benefits expected to be realized with RMAT, such as keeping the US globally competitive in the field. They provide a tally of products receiving the special

Read More


Using CAR T-cell Therapy in Older Patients With Aggressive Lymphoma

Article Highlights CAR T-cell therapy is gaining traction in relapsed/refractory lymphoma in older patients with aggressive disease. As a result of prospective trials investigating CAR T-cell therapy, there is potential that older patients with lymphoma can be spared multiple lines of chemotherapy and its resultant toxicities while still having long-term clinical benefit. Toxicities are still

Read More


ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer

The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone. After 42 months of follow-up, the survival rate was 70% for women who took the combination therapy compared with 46% for women who

Read More


Back-and-forth exchanges boost children’s brain response to language

Study finds engaging young children in conversation is more important for brain development than “dumping words” on them. A landmark 1995 study found that children from higher-income families hear about 30 million more words during their first three years of life than children from lower-income families. This “30-million-word gap” correlates with significant differences in tests

Read More


Advanced Therapies News

Source ARM Organovo Collaborates With MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney DiseaseMay 30, 2019 – (Organovo) – This multi-organizational effort integrates Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise.  The collaboration has been made possible through generous

Read More